LAKE FOREST, Ill (News release) -- Pactiv Evergreen Inc. announced that all required regulatory approvals have been received in connection with the Company's previously announced definitive agreement to be acquired by Novolex® for $18.00 per share in cash.

As a result, the transaction is now expected to close on April 1, 2025, subject to satisfaction of other customary closing conditions. Upon the completion of the transaction, Pactiv Evergreen will become a privately held company, and its common stock will no longer be listed on Nasdaq.

Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC are acting as financial advisors and Paul Hastings LLP is acting as legal advisor to Pactiv Evergreen.